Emalex Biosciences, LLC is a biopharmaceutical company dedicated to the development of new treatments for rare and orphan neurological conditions. Ecopipam, its first development candidate, is a novel compound that has been studied as a potential treatment for many central nervous system (CNS) disorders, including pediatric Tourette Syndrome. The latter is a childhood-onset neurodevelopmental condition characterized by motor and vocal tics for which very few safe and effective therapies exist.

Horizon Technology Finance

Valor Equity Partners

Paragon Biosciences

Fidelity Management and Research Company

Bain Capital Life Sciences

Emalex Biosciences

We are conducting a Phase 3 clinical trial for a potential therapeutic to treat Tourette syndrome. The study evaluates a therapeutic in children, adolescents and adults. Sites are in North America and Europe. Study details are available here: https://lnkd.in/gm_Sxfvy

#tourettesyndrome #clinicaltrial 

Remembering Dr. Martin Luther King, Jr. today. His commitment to combating injustice and fostering inclusivity continues to inspire. #martinlutherkingjr 

Emalex Biosciences is a biopharmaceutical company dedicated to developing new treatments for rare and orphan neurological conditions. Their first development candidate, Ecopipam, is a novel compound studied as a potential treatment for central nervous system (CNS) disorders, including pediatric Tourette Syndrome.

COM:EMALEXBIOSCIENCES

Emalex Biosciences, LLC

Filings Not Available